IPO Databook: HCW Biologics (HCWB US) - Oct 2026

111 Views22 Aug 2026 10:07

SUMMARY

HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, cancer, and senescence-associated dysplasia.
HCW9302 is being evaluated in alopecia areata, with a full Phase 1 readout expected in Q4 2026. Anktiva® was approved by the FDA in April 2024.
The company is negotiating with creditors for debt forbearance and has reported material weaknesses in internal control over financial reporting.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream